[
  {
    "ts": null,
    "headline": "LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal",
    "summary": "Eli Lilly is set to buy Orna Therapeutics for $2.4B to expand in vivo CAR-T and circular RNA capabilities, signaling a long-term push to diversify its pipeline.",
    "url": "https://finnhub.io/api/news?id=79a9714db93496723c0a64fbffd847d94868d221dbf0af3ac386612841db3969",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770739800,
      "headline": "LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal",
      "id": 139033420,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly is set to buy Orna Therapeutics for $2.4B to expand in vivo CAR-T and circular RNA capabilities, signaling a long-term push to diversify its pipeline.",
      "url": "https://finnhub.io/api/news?id=79a9714db93496723c0a64fbffd847d94868d221dbf0af3ac386612841db3969"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's 2025 Surge Sets the Stage for Another Big Year in 2026",
    "summary": "LLY posts 45% revenue growth to $65.2B in 2025 as GLP-1 drugs power results, and guides $80-$83B in sales with EPS up over 40% in 2026.",
    "url": "https://finnhub.io/api/news?id=71a4cd03a6f60b21d0109cc82686df5f2ab40e0187e29438be5d0b21a5d69c5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770738540,
      "headline": "Eli Lilly's 2025 Surge Sets the Stage for Another Big Year in 2026",
      "id": 139033421,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY posts 45% revenue growth to $65.2B in 2025 as GLP-1 drugs power results, and guides $80-$83B in sales with EPS up over 40% in 2026.",
      "url": "https://finnhub.io/api/news?id=71a4cd03a6f60b21d0109cc82686df5f2ab40e0187e29438be5d0b21a5d69c5a"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy",
    "summary": "AstraZeneca delivered robust 2025 results, with 9% product sales growth and a 23.4% operating margin, and raised its dividend. Click for this AZN stock update.",
    "url": "https://finnhub.io/api/news?id=d67ba7e66543e46610062082f956a8cd028b5c15dcc3bf3542bdeecd11a548d5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770738189,
      "headline": "AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy",
      "id": 139035595,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2231914284/image_2231914284.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca delivered robust 2025 results, with 9% product sales growth and a 23.4% operating margin, and raised its dividend. Click for this AZN stock update.",
      "url": "https://finnhub.io/api/news?id=d67ba7e66543e46610062082f956a8cd028b5c15dcc3bf3542bdeecd11a548d5"
    }
  },
  {
    "ts": null,
    "headline": "INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales",
    "summary": "Incyte posts a Q4 EPS miss but a 28% revenue jump, fueled by Jakafi and Opzelura strength, as product sales top estimates.",
    "url": "https://finnhub.io/api/news?id=9ead684b7768bc0991e0c75241c57d202ab4525efc0f283450bbe30a0c5c9080",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770737880,
      "headline": "INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales",
      "id": 139033422,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Incyte posts a Q4 EPS miss but a 28% revenue jump, fueled by Jakafi and Opzelura strength, as product sales top estimates.",
      "url": "https://finnhub.io/api/news?id=9ead684b7768bc0991e0c75241c57d202ab4525efc0f283450bbe30a0c5c9080"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know.",
    "summary": "Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next?",
    "url": "https://finnhub.io/api/news?id=0e091ade19d0f68851c9fb0b148299cc24b21fb9e8e98cc37822b31e0fa7ed1f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770734100,
      "headline": "Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know.",
      "id": 139031850,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next?",
      "url": "https://finnhub.io/api/news?id=0e091ade19d0f68851c9fb0b148299cc24b21fb9e8e98cc37822b31e0fa7ed1f"
    }
  },
  {
    "ts": null,
    "headline": "Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study",
    "summary": "The results vaulted Nektar’s market value to over $1 billion amid expectations the drug might prove a challenger to widely used medications like Dupixent.",
    "url": "https://finnhub.io/api/news?id=3eedf4b876764d5a39ea601ef81e41d4e40f6f3efc92c8566270779d4bf04b0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770725580,
      "headline": "Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study",
      "id": 139033423,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The results vaulted Nektar’s market value to over $1 billion amid expectations the drug might prove a challenger to widely used medications like Dupixent.",
      "url": "https://finnhub.io/api/news?id=3eedf4b876764d5a39ea601ef81e41d4e40f6f3efc92c8566270779d4bf04b0b"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Ugly Guidance, But Stock Refuses To Break Down Further",
    "summary": "Novo Nordisk stock is a Buy despite a disappointing negative 2026 sales guidance amid fierce competition from Eli Lilly and compounders. Click for more on NVO.",
    "url": "https://finnhub.io/api/news?id=6e9f3826042fb3e611eae17c3d287de18046c93eb164513283a194baeee03878",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770719611,
      "headline": "Novo Nordisk: Ugly Guidance, But Stock Refuses To Break Down Further",
      "id": 139031646,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk stock is a Buy despite a disappointing negative 2026 sales guidance amid fierce competition from Eli Lilly and compounders. Click for more on NVO.",
      "url": "https://finnhub.io/api/news?id=6e9f3826042fb3e611eae17c3d287de18046c93eb164513283a194baeee03878"
    }
  },
  {
    "ts": null,
    "headline": "Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains?",
    "summary": "The stock has climbed in the triple digits over the past three years.",
    "url": "https://finnhub.io/api/news?id=682c7725c98f22419680c3f7a04bc547be3ff5671ea555bd7c3364259105e2ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770714600,
      "headline": "Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains?",
      "id": 139027727,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The stock has climbed in the triple digits over the past three years.",
      "url": "https://finnhub.io/api/news?id=682c7725c98f22419680c3f7a04bc547be3ff5671ea555bd7c3364259105e2ed"
    }
  },
  {
    "ts": null,
    "headline": "Caterpillar To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesday",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=d8622e5666ff2129c2695d6b40a60060e921fd156b9e6073caa35ee7d34c4c8a",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770714425,
      "headline": "Caterpillar To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesday",
      "id": 139029078,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/10/Caterpillar-Inc--NYSE-CAT.jpeg?width=2048&height=1536",
      "related": "LLY",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=d8622e5666ff2129c2695d6b40a60060e921fd156b9e6073caa35ee7d34c4c8a"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Launches Suit to Knock Out Hims & Hers’ Weight Loss Knockoffs",
    "summary": "Novo’s Copenhagen-listed shares rose 5.2% on Monday. New York-listed shares in Hims & Hers, meanwhile, shed an Ozempic-like 16% in volume.",
    "url": "https://finnhub.io/api/news?id=f21610d69f1500271ae60d1b3d11ab764ff23a12c287f86f6825cb08ea93a5c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770699660,
      "headline": "Novo Nordisk Launches Suit to Knock Out Hims & Hers’ Weight Loss Knockoffs",
      "id": 139028384,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo’s Copenhagen-listed shares rose 5.2% on Monday. New York-listed shares in Hims & Hers, meanwhile, shed an Ozempic-like 16% in volume.",
      "url": "https://finnhub.io/api/news?id=f21610d69f1500271ae60d1b3d11ab764ff23a12c287f86f6825cb08ea93a5c2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Uses GLP-1 Strength To Build Genetic And Oncology Portfolio",
    "summary": "Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics in a deal valued at up to US$2.4b, expanding into in vivo cell and genetic therapies for autoimmune diseases. The company also extended its partnership with Innovent Biologics to advance oncology and immunology drug candidates for global markets. These moves broaden Eli Lilly’s focus beyond obesity treatments toward RNA based therapies and cell engineering for conditions with significant unmet medical need. Eli Lilly, known for its...",
    "url": "https://finnhub.io/api/news?id=0dd353cc6738687a877976cd65ddecca18236e4cf34a42d37412db0c31793b34",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770683034,
      "headline": "Eli Lilly Uses GLP-1 Strength To Build Genetic And Oncology Portfolio",
      "id": 138973911,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics in a deal valued at up to US$2.4b, expanding into in vivo cell and genetic therapies for autoimmune diseases. The company also extended its partnership with Innovent Biologics to advance oncology and immunology drug candidates for global markets. These moves broaden Eli Lilly’s focus beyond obesity treatments toward RNA based therapies and cell engineering for conditions with significant unmet medical need. Eli Lilly, known for its...",
      "url": "https://finnhub.io/api/news?id=0dd353cc6738687a877976cd65ddecca18236e4cf34a42d37412db0c31793b34"
    }
  }
]